All In Biotech

Drug Trial Radar · NCT06161688

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Placebo-Controlled, Randomized Trial of Ensitrelvir (S-217622) for Viral Persistence and Inflammation in People Experiencing Long COVID (PREVAIL-LC)

Last checked: Nov 20, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

40

Actual

Start

Apr 9, 2024

Primary completion

Dec 20, 2024

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Timothy HenrichAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shionogi Inc.
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult population.

Conditions

  • Long COVID
  • Post Acute Sequelae of COVID-19
  • Post-Acute COVID-19

Interventions

  • EnsitrelvirDrug

    Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days

  • PlaceboOther

    Matching placebo for Ensitrelvir

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Physical Health Summary ScoreTime frame: Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCSF/Zuckerberg San Francisco General Hospital

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.